Moderna Shares Surge as Oncology Pipeline Ignites Investor Optimism
Piper Sandler raised its price target on Moderna from $69 to $77, maintaining an Overweight rating. Strong momentum in the oncology pipeline is fueling the rally.
Piper Sandler raised its price target on Moderna from $69 to $77, maintaining an Overweight rating. Strong momentum in the oncology pipeline is fueling the rally.
Decision due Aug 5, 2026. Potential 2026–27 launch.
Moderna names Ester Banque, ex-Zoetis/Novartis, as Chief Commercial Officer as it prepares for potential 2027 launches of combined flu-COVID, standalone flu, and norovirus vaccines. FDA advisory on mFLUSIVA this week.
Moderna stock rises as it works on a hantavirus vaccine after a cruise outbreak, but the disease is rare and vaccines will take years.
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.